One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Grifols, S.A. logo
Grifols, S.A. GRFS
$ 8.49 -1.51%
report update icon

Quarterly report 2022-Q4
added 11-02-2026

Grifols, S.A. Financial Statements 2024-2011 | GRFS

Annual Financial Statements Grifols, S.A.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

4.52 B 4.28 B 6.81 B 8.42 B -395 B -509 B -1.41 T -732 B 2.14 B -1.49 T -1.86 T -11.1 T -4.93 T -627 B

Shares

680 M 680 M 680 M 682 M -24.9 B -24.9 B -77.7 B -36.7 B 127 M -103 B -108 B -561 B -370 B -103 B

Historical Prices

6.65 6.3 10 12.4 15.8 20.4 18.2 19.9 15.6 13.7 14.1 18 12.1 5.73

Net Income

213 M 164 M 248 M 265 M 619 M 986 M 857 M 730 M 881 M 849 M 712 M 653 M 521 M 110 M

Revenue

7.21 B 6.59 B 6.06 B 4.93 B 5.34 B 5.1 B 4.49 B 4.32 B 4.05 B 3.93 B 3.36 B 2.74 B 2.62 B 1.8 B

Cost of Revenue

4.42 B 4.11 B 3.85 B 2.97 B 3.08 B 2.76 B 2.44 B 2.17 B 2.14 B 2 B - - - -

Gross Profit

2.79 B 2.48 B 2.21 B 1.96 B 2.26 B 2.34 B 2.05 B 2.15 B 1.91 B 1.93 B 1.7 B 1.42 B 1.33 B 1.8 B

Operating Income

1.19 B 782 M 782 M 595 M 996 M 1.13 B 994 M 1 B 939 M 970 M - - - -

EBITDA

1.19 B 782 M 782 M 595 M 996 M 1.13 B 994 M 1 B 545 M 542 M 474 M 349 M 262 M 92.8 M

Operating Expenses

1.64 B 1.77 B 1.56 B 1.42 B 1.28 B 1.22 B 1.06 B 1.15 B 973 M 961 M 842 M 682 M 670 M 1.05 B

General and Administrative Expenses

1.26 B 1.37 B 1.2 B 1.06 B - - - - - - - - - -

All numbers in EUR currency

Quarterly Income Statement Grifols, S.A.

2024-Q4 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

680 M 680 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

213 M 164 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

7.21 B 6.59 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

4.42 B 4.11 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

2.79 B 2.48 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

1.19 B 782 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

1.19 B 782 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

1.64 B 1.77 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

1.26 B 1.37 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Grifols, S.A. GRFS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Grifols, S.A. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.13 -3.75 % $ 210 K usaUSA
AC Immune SA AC Immune SA
ACIU
$ 2.11 -0.24 % $ 213 M schweizSchweiz
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 9.71 -2.8 % $ 1.36 B franceFrance
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 0.7 -6.1 % $ 154 M usaUSA
Altimmune Altimmune
ALT
$ 1.38 -9.8 % $ 122 M usaUSA
AnaptysBio AnaptysBio
ANAB
$ 46.44 1.82 % $ 1.35 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 270.27 -0.34 % $ 16.4 B danmarkDanmark
Precision BioSciences Precision BioSciences
DTIL
$ 7.1 0.64 % $ 91.1 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.03 0.75 % $ 220 M israelIsrael
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.13 -1.79 % $ 2.03 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.07 -2.29 % $ 285 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 3.99 0.71 % $ 325 M usaUSA
Exelixis Exelixis
EXEL
$ 68.26 -0.35 % $ 18.5 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 133.97 -1.46 % $ 6.66 B usaUSA
Curis Curis
CRIS
$ 0.6 10.65 % $ 7.9 M usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 77.98 1.54 % $ 14.9 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 7.31 -2.6 % $ 1.53 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.1 -3.13 % $ 215 M britainBritain
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.64 17.17 % $ 56.6 M israelIsrael
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 12.93 -2.34 % $ 836 M usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 15.56 13.57 % $ 64.8 M canadaCanada
Immutep Limited Immutep Limited
IMMP
$ 3.29 0.92 % $ 4.79 B australiaAustralia
BeyondSpring BeyondSpring
BYSI
$ 0.46 -18.4 % $ 18.9 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 1.06 3.43 % $ 107 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.48 -2.17 % $ 206 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 0.41 -14.71 % $ 48 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.63 -1.46 % $ 1.84 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 1.02 -3.42 % $ 102 M franceFrance
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 3.13 17.67 % $ 113 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 2.07 5.61 % $ 11.8 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 26.02 1.84 % $ 824 M usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
$ 48.61 -1.28 % $ 197 B britainBritain
CorMedix CorMedix
CRMD
$ 4.51 -3.53 % $ 325 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 40.19 0.09 % $ 3.61 B schweizSchweiz
Forte Biosciences Forte Biosciences
FBRX
$ 76.99 0.03 % $ 997 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.59 0.04 % $ 63.5 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 13.29 -2.14 % $ 380 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 51.27 -0.74 % $ 6.16 M usaUSA
Immunome Immunome
IMNM
$ 16.67 -2.97 % $ 1.46 B usaUSA
Immunic Immunic
IMUX
$ 7.53 2.73 % $ 1.17 B usaUSA
Immunovant Immunovant
IMVT
$ 33.18 -0.09 % $ 6.05 B usaUSA
Incyte Corporation Incyte Corporation
INCY
$ 117.79 -1.09 % $ 23 B usaUSA
Insmed Incorporated Insmed Incorporated
INSM
$ 120.17 -1.39 % $ 23.9 B usaUSA
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
$ 7.49 -0.6 % $ 2.68 M usaUSA
Dyadic International Dyadic International
DYAI
$ 0.32 1.27 % $ 11.6 M usaUSA
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
$ 4.79 -1.75 % $ 775 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 3.73 -0.67 % $ 284 M usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
$ 272.65 -2.17 % $ 656 B usaUSA
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
$ 94.99 -0.13 % $ 7.05 B usaUSA